

November 17, 2017 by 4 p.m. If selected for presentation, any presentation materials must be emailed to Paula Caposino (see **FOR FURTHER INFORMATION CONTACT**) no later than November 21, 2017. No commercial or promotional material will be permitted to be presented or distributed at the public workshop.

*Streaming Webcast of the public workshop:* This public workshop will also be Webcast. The Webcast link will be available on the registration Web page after November 21, 2017. Organizations are requested to register all participants, but to view using one connection per location.

If you have never attended a Connect Pro event before, test your connection at [https://collaboration.fda.gov/common/help/en/support/meeting\\_test.htm](https://collaboration.fda.gov/common/help/en/support/meeting_test.htm). To get a quick overview of the Connect Pro program, visit [http://www.adobe.com/go/connectpro\\_overview](http://www.adobe.com/go/connectpro_overview). FDA has verified the Web site addresses in this document, as of the date this document publishes in the **Federal Register**, but Web sites are subject to change over time.

*Transcripts:* Please be advised that as soon as a transcript of the public workshop is available, it will be accessible at <https://www.regulations.gov>. It may be viewed at the Dockets Management Staff (see **ADDRESSES**). A link to the transcript will also be available approximately 45 days after the public workshop on the Internet at <http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm>. (Select this public workshop from the posted events list).

#### IV. References

The following references are on display in the Dockets Management Staff (see **ADDRESSES**) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at <https://www.regulations.gov>.

1. "National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes." *Circulation*, 2007; 115, 356–375.
2. "Universal Definition of Myocardial Infarction." *Circulation*, 2007; 116, 2634–2653.

Dated: July 20, 2017.

**Anna K. Abram,**

*Deputy Commissioner for Policy, Planning, Legislation, and Analysis.*

[FR Doc. 2017–16007 Filed 7–28–17; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2017–N–0001]

#### Developing a Framework for Regulatory Use of Real-World Evidence; Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public workshop.

**SUMMARY:** The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "Developing a Framework for Regulatory Use of Real-World Evidence." Convened by the Duke-Robert J. Margolis, MD, Center for Health Policy at Duke University and supported by a cooperative agreement with FDA, the purpose of the public workshop is to bring the stakeholder community together to discuss a variety of topics related to the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulatory decision making. Topics will include an update on FDA's activities to address the use of RWE in regulatory decisions and the development of a framework for tackling challenges related to RWE's regulatory acceptability. In addition, panelists will discuss opportunities to improve data development activities, study designs, and analytical methods used to create robust RWE.

**DATES:** The public workshop will be held on September 13, 2017, from 9 a.m. to 4:30 p.m., Eastern Time.

**ADDRESSES:** The public workshop will be held at the Conference Center at 1777 F Street NW., Washington, DC 20006. For additional travel and hotel information, please refer to the following Web site: <https://healthpolicy.duke.edu/events/public-workshop-developing-framework-regulatory-use-real-world-evidence>. There will also be a live webcast for those unable to attend the meeting in person (see *Streaming Webcast of Public Workshop*).

**FOR FURTHER INFORMATION CONTACT:** Kayla Garvin, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New

Hampshire Ave., Bldg. 51, Rm. 6314, Silver Spring, MD 20993, (301) 796–7578, [Kayla.Garvin@fda.hhs.gov](mailto:Kayla.Garvin@fda.hhs.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. Background

RWD (data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources) and RWE (clinical evidence regarding the usage and potential benefits or risks of a drug derived from analysis of RWD) are increasingly being used by multiple stakeholders within the health care system. Payers may rely on RWD and RWE to refine formularies or assist in coverage decisions. Physicians and professional societies can utilize RWE to further tailor clinical practice guidelines and decision-support tools. Medical product developers can use RWE to further develop a product's benefit-risk profile, monitor postmarket safety and adverse events, or generate additional hypotheses for continued clinical development.

The 21st Century Cures Act, section 3022 (Pub. L. 114–255), enacted on December 13, 2016, directed FDA to establish a program to evaluate the potential use of RWE. The framework of the program was to include information describing the sources of RWE, the gaps in data collection, standards and methods for collection and analysis, and the priority areas and challenges.

To date, RWD and RWE have been used in very specific regulatory contexts. Some treatments for rare diseases, for example, have utilized RWE as part of the historical controls used for clinical study and, ultimately, regulatory submission. Postmarket safety surveillance has also relied heavily on RWD-generating networks. As part of exploring the opportunities for enhanced use of these types of data and evidence in additional regulatory decision-making contexts, FDA is seeking input on the opportunities and challenges in using RWE to support the approval of a new indication for an already approved drug, and to help support or satisfy postapproval study requirements.

This public workshop is being held to engage external stakeholders in discussions around the current state of RWE development and potential challenge areas for using RWE in regulatory decisions beyond postmarket safety surveillance.

##### II. Topics for Discussion at the Public Workshop

During the course of the public workshop, speakers and participants will cover a range of issues related to

the development of RWE and its applicability within specific regulatory decision-making contexts. This will include, but not be limited to, challenges related to RWD collection and quality, innovative methods for developing RWE from RWD, and promising areas for RWE pilot demonstrations.

### III. Participating in the Public Workshop

**Registration:** To register for the public workshop, please visit the following Web site before September 12, 2017: <https://healthpolicy.duke.edu/events/public-workshop-developing-framework-regulatory-use-real-world-evidence>. There will be no onsite registration. Please provide complete contact information for each attendee, including name, title, affiliation, address, email, and telephone.

Registration is free and based on space availability, with priority given to early registrants. Early registration is recommended because seating is limited; therefore, FDA may limit the number of participants from each organization. A 1-hour lunch break is scheduled, but food will not be provided. There are multiple restaurants within walking distance of the Conference Center.

If you need special accommodations due to a disability, please contact Joanna Higgison at the Duke-Margolis Center for Health Policy, 908-432-4872, [joanna.higgison@duke.edu](mailto:joanna.higgison@duke.edu), no later than September 6, 2017.

**Streaming Webcast of the Public Workshop:** This public workshop will also be webcast and archived video footage will be available at the Duke-Margolis Web site (<https://healthpolicy.duke.edu/events/public-workshop-developing-framework-regulatory-use-real-world-evidence>) following the workshop. Persons interested in viewing the live webcast must register online by September 12, 2017, at 5 p.m. Eastern Time (see *Registration*). Early registration is recommended because webcast connections are limited. Organizations are requested to register all participants, but to view using one connection per location whenever possible. Webcast participants will be sent technical system requirements in advance of the event. Prior to joining the streaming webcast of the public workshop, it is recommended that you review these technical system requirements.

FDA has verified the Web site addresses in this document, as of the date this document publishes in the **Federal Register**, but Web sites are subject to change over time.

**Meeting Materials:** All event materials will be provided to registered attendees via email prior to the workshop and publicly available at the Duke-Margolis Web site (<https://healthpolicy.duke.edu/events/public-workshop-developing-framework-regulatory-use-real-world-evidence>).

**Transcripts:** Please be advised that transcripts will not be available.

Dated: July 25, 2017.

**Leslie Kux,**

*Associate Commissioner for Policy.*

[FR Doc. 2017-16021 Filed 7-28-17; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Committee on Vital and Health Statistics: Meeting

Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) announces the following advisory committee meeting.

**Name:** National Committee on Vital and Health Statistics (NCVHS), Full Committee and Population Health Subcommittee Meetings.

**Dates and Times:**

Monday, September 11, 2017: 9:00 a.m.–5:45 p.m.

Tuesday, September 12, 2017: 8:30 a.m.–5:00 p.m.

Wednesday, September 13, 2017: 8:45 a.m.–5:30 p.m.

Thursday, September 14, 2017: 8:30 a.m.–3:15 p.m.

**Place:** U.S. Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue SW., Room 705A, Washington, DC 20201.

**Status:** Open.

**Purpose:** At the September 11–12, 2017 hearing, the Population Health Subcommittee will focus on Next Generation Vital Statistics. The purpose of the hearing is to assess the current state of the national vital statistics system (NVSS) to address concerns regarding sustainability and viability of the system infrastructure. The focus will be on the system's capacity to provide timely, high quality, secure vital administrative and statistical data for identity establishment and protection, identification of trends in disease and epidemics, *e.g.*, the recent surge in opioid-related deaths, and a host of critical uses for research, finance, planning, public records and services.

At the September 13–14, 2017 full meeting, the Committee will hear presentations, hold discussions on

several health data policy topics and begin to formulate its work plan for 2018. To inform the work plan, the Committee will be briefed by the Commission on Evidence-based Policymaking (CEP) regarding the release of its report and recommendations as well as hear from HHS leadership regarding data needs and gaps. A panel will be held to discuss the new topic “Beyond HIPAA,” an exploration of challenges that extend beyond HIPAA and the range of policy options that may be available to the Department related to privacy, security and access measures to protect individually identifiable health information in an environment of electronic networking and multiple uses of data. Additional discussions are planned on the Predictability Roadmap project in follow up to a Standards Subcommittee workshop focused on possible approaches to improve the predictability and improvements in the adoption and processes related to updating standards and operating rules for electronic administrative transactions (*e.g.* claims, eligibility, electronic funds transfer); and on terminology & vocabulary development, maintenance, and dissemination processes. The Committee also plans to finalize the update to its strategic plan and selection criteria for undertaking new Committee projects. The times and topics are subject to change. Please refer to the posted agenda for any updates.

**Contact person for more information:** Substantive program information may be obtained from Rebecca Hines, MHS, Executive Secretary, NCVHS, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782, telephone (301) 458-4715. Summaries of meetings and a roster of Committee members are available on the home page of the NCVHS Web site: <http://www.ncvhs.hhs.gov/>, where further information including an agenda and instructions to access the audio broadcast of the meetings will also be posted. Should you require reasonable accommodation, please contact the CDC Office of Equal Employment Opportunity on (770) 488-3210 as soon as possible.

Dated: July 25, 2017.

**Laina Bush,**

*Deputy Assistant Secretary for Planning and Evaluation, Office of the Assistant Secretary for Planning and Evaluation.*

[FR Doc. 2017-16036 Filed 7-28-17; 8:45 am]

**BILLING CODE 4151-05-P**